Wells Fargo
BRTX icon

Wells Fargo’s BioRestorative Therapies BRTX Stock Holding History

Wells Fargo’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$1.45K – 7130
2025
Q3 		$1.45K Buy
+1,000
New +$1.55K ﹤0.01% 6227
2024
Q3 		– Sell
-965
Closed -$1.96K – 6921
2024
Q2 		$1.96K Sell
965
-515
-35% -$742 ﹤0.01% 6020
2024
Q1 		$2.04K Sell
1,480
-471
-24% -$725 ﹤0.01% 6033
2023
Q4 		$3.4K Sell
1,951
-7,394
-79% -$14.1K ﹤0.01% 6015
2023
Q3 		$16.7K Sell
9,345
-2,217
-19% -$5.59K ﹤0.01% 5661
2023
Q2 		$51K Buy
11,562
+11,540
+52,455% +$55.2K ﹤0.01% 5420
2023
Q1 		$75 Hold
22
– – ﹤0.01% 7001
2022
Q4 		$61 Buy
22
+1
+5% +$3 ﹤0.01% 6943
2022
Q3 		$0 Buy
21
+3
+17% +$9 ﹤0.01% 6685
2022
Q2 		$0 Buy
18
+2
+13% +$8 ﹤0.01% 6822
2022
Q1 		$0 Buy
16
+2
+14% +$9 ﹤0.01% 7083
2021
Q4 		$0 Buy
+14
New +$80 ﹤0.01% 7234

Other funds holding BRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NF
Napier Financial Braintree, Massachusetts $436M AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo's BRTX Position: Q4 2025 in Review

Wells Fargo sold out of BioRestorative Therapies (BRTX) in Q4 2025, closing a stake of 1,000 shares — an estimated $1.45K sold.

Wells Fargo first reported a position in BRTX in Q4 2021 and held it in 12 quarters. The position peaked at $51K in Q2 2023. 13 funds tracked by Wall St. Rank hold BRTX as of Q4 2025.

  • Wells Fargo reported no remaining BioRestorative Therapies position as of Q4 2025 after selling out during the quarter.
  • Wells Fargo sold 1,000 BioRestorative Therapies shares in Q4 2025, an estimated $1.45K.
  • Wells Fargo first reported a position in BioRestorative Therapies in Q4 2021 and held it in 12 quarters.
  • Wells Fargo's BioRestorative Therapies position peaked at $51K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2025.

Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.